肝胆道疾患(Hepatobiliary Disease):世界の治験レビュー(2015年上半期版)

◆英語タイトル:Hepatobiliary Disease Global Clinical Trials Review, H1, 2015
◆商品コード:GDHC2643CTIDB
◆発行会社(調査会社):GlobalData
◆発行日:2015年4月27日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における肝胆道疾患(Hepatobiliary Disease) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - 肝胆道疾患(Hepatobiliary Disease)
  - 当レポートの概要
・肝胆道疾患(Hepatobiliary Disease):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Hepatobiliary Disease Global Clinical Trials Review, H1, 2015

Summary

GlobalData’s clinical trial report, “Hepatobiliary Disease Global Clinical Trials Review, H1, 2015″ provides data on the Hepatobiliary Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatobiliary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatobiliary Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Hepatobiliary Disease 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Hepatobiliary Disease to Gastrointestinal Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Hepatobiliary Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Unaccomplished Trials of Hepatobiliary Disease 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Prominent Drugs 23
Clinical Trial Profiles 24
Clinical Trial Overview of Top Companies 24
Pfizer Inc. 24
Clinical Trial Overview of Pfizer Inc. 24
Clinical Trial Overview of Top Institutes / Government 25
Hiroshima University Hospital 25
Clinical Trial Overview of Hiroshima University Hospital 25
Hokkaido University Hospital 26
Clinical Trial Overview of Hokkaido University Hospital 26
Osaka University 27
Clinical Trial Overview of Osaka University 27
The University of Tokyo 28
Clinical Trial Overview of The University of Tokyo 28
Chiba University 29
Clinical Trial Overview of Chiba University 29
Guangdong Science and Technology Department 30
Clinical Trial Overview of Guangdong Science and Technology Department 30
Haydarpasa Numune State Hospital 31
Clinical Trial Overview of Haydarpasa Numune State Hospital 31
Hokkaido University School of Medicine 32
Clinical Trial Overview of Hokkaido University School of Medicine 32
Japanese Endoscopist & IVRists group for Biliary Tract Cancer 33
Clinical Trial Overview of Japanese Endoscopist & IVRists group for Biliary Tract Cancer 33
Kyoto Prefectural University of Medicine 34
Clinical Trial Overview of Kyoto Prefectural University of Medicine 34
Five Key Clinical Profiles 35
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 51

List of Tables
Hepatobiliary Disease Therapeutics, Global, Clinical Trials by Region, 2015* 6
Hepatobiliary Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Hepatobiliary Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Hepatobiliary Disease Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 9
Hepatobiliary Disease Therapeutics Clinical Trials, Europe, Top Countries, 2015* 10
Hepatobiliary Disease Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Proportion of Hepatobiliary Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 12
Hepatobiliary Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Hepatobiliary Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Hepatobiliary Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 15
Hepatobiliary Disease Therapeutics, Global, Clinical Trials by Phase, 2015* 16
Hepatobiliary Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 17
Hepatobiliary Disease Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Hepatobiliary Disease Therapeutics, Global, Withdrawn Clinical Trials, 2015* 19
Hepatobiliary Disease Therapeutics, Global, Terminated Clinical Trials, 2015* 19
Hepatobiliary Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20
Hepatobiliary Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 21
Hepatobiliary Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22
Hepatobiliary Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 23
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 24
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Hiroshima University Hospital, 2015* 25
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Hokkaido University Hospital, 2015* 26
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Osaka University, 2015* 27
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Tokyo, 2015* 28
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Chiba University, 2015* 29
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Guangdong Science and Technology Department, 2015* 30
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Haydarpasa Numune State Hospital, 2015* 31
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Hokkaido University School of Medicine, 2015* 32
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Japanese Endoscopist & IVRists group for Biliary Tract Cancer, 2015* 33
Hepatobiliary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyoto Prefectural University of Medicine, 2015* 34

List of Figures
Hepatobiliary Disease Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Hepatobiliary Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Hepatobiliary Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Hepatobiliary Disease Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 9
Hepatobiliary Disease Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* 10
Proportion of Hepatobiliary Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* 12
Hepatobiliary Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 13
Hepatobiliary Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 14
Proportion of Hepatobiliary Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* 15
Hepatobiliary Disease Therapeutics, Global, Clinical Trials by Phase (%), 2015* 16
Hepatobiliary Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 17
Hepatobiliary Disease Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Hepatobiliary Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20
Hepatobiliary Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 21
Hepatobiliary Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 23
GlobalData Methodology 50

【レポートのキーワード】

肝胆道疾患(Hepatobiliary Disease)、治験、臨床試験、治験、治療薬

★調査レポート[肝胆道疾患(Hepatobiliary Disease):世界の治験レビュー(2015年上半期版)] (コード:GDHC2643CTIDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝胆道疾患(Hepatobiliary Disease):世界の治験レビュー(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆